Clinical trial NCT00089869: A Combination of Two Currently Approved Drugs to Enhance the Treatment of Schizophrenia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Schizophrenia
Lead sponsor: Eli Lilly and Company
Sponsor class: INDUSTRY
First posted: 2004-08-18
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: no
Primary purpose: TREATMENT

Brief summary: Study of a medication for the treatment of Schizophrenia in patients who are already taking Abilify, Risperdal, Seroquel, Zyprexa


Eligibility criteria: Inclusion Criteria:

* Must have a clinical diagnosis of Schizophrenia
* Must be at least 18 years of age and not older than 55 years of age
* Must have been stable on a dose of Abilify, Risperdal, Seroquel, or Zyprexa for the past 8 weeks
* Women of childbearing potential must be using a medically accepted means of contraception
* Must be able to swallow capsules

Exclusion Criteria:

* Has serious health problems other than Schizophrenia
* Takes an antidepressant for depression
* Takes insulin for diabetes
* Have a history of alcohol or drug dependence (except for nicotine and caffeine) within the past 6 months

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Cerritos
country: United States
facility: "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."
state: California
city: Chula Vista
country: United States
facility: "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician.
state: California
city: Garden Grove
country: United States
facility: For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
state: California
city: San Diego
country: United States
facility: "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."
state: California
city: New Haven
country: United States
facility: "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."
state: Connecticut
city: New Haven
country: United States
facility: For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
state: Connecticut
city: Atlanta
country: United States
facility: "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."
state: Georgia
city: Chicago
country: United States
facility: "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."
state: Illinois
city: Indianapolis
country: United States
facility: "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."
state: Indiana
city: Iowa City
country: United States
facility: "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."
state: Iowa
city: Minneapolis
country: United States
facility: "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."
state: Minnesota
city: Lebanon
country: United States
facility: "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."
state: New Hampshire
city: New York
country: United States
facility: "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."
state: New York
city: Butner
country: United States
facility: "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."
state: North Carolina
city: Chapel Hill
country: United States
facility: "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."
state: North Carolina
city: Okalahoma City
country: United States
facility: "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."
state: Oklahoma
city: Austin
country: United States
facility: "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."
state: Texas
city: Irving
country: United States
facility: For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
state: Texas
city: Irvin
country: United States
facility: "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."
state: Texas
city: San Antonio
country: United States
facility: "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."
state: Texas
Study officials:
References: